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Abstract
We investigated the role of Lef1, one of the four transcription factors that transmit Wnt signaling to the genome, in the
regulation of bone mass. Microcomputed tomographic analysis of 13- and 17-week-old mice revealed significantly reduced
trabecular bone mass in Lef1
+/2 females compared to littermate wild-type females. This was attributable to decreased
osteoblast activity and bone formation as indicated by histomorphometric analysis of bone remodeling. In contrast to
females, bone mass was unaffected by Lef1 haploinsufficiency in males. Similarly, females were substantially more
responsive than males to haploinsufficiency in Gsk3b, a negative regulator of the Wnt pathway, displaying in this case a high
bone mass phenotype. Lef1 haploinsufficiency also led to low bone mass in males lacking functional androgen receptor (AR)
(tfm mutants). The protective skeletal effect of AR against Wnt-related low bone mass is not necessarily a result of direct
interaction between the AR and Wnt signaling pathways, because Lef1
+/2 female mice had normal bone mass at the age of
34 weeks. Thus, our results indicate an age- and gender-dependent role for Lef1 in regulating bone formation and bone
mass in vivo. The resistance to Lef1 haploinsufficiency in males with active AR and in old females could be due to the
reduced bone turnover in these mice.
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Introduction
The wingless/Wnt family of secreted glycoproteins has critical
roles in cell growth and differentiation, and is highly conserved
among vertebrates, flies, and primitive multicellular organisms
[1,2]. In mammals, the canonical Wnt pathway is pivotal to
embryogenesis and tumorigenesis as well as in the maintenance
and regeneration of tissues such as skin, intestine, liver, cardiac
muscle, and the nervous system [1–7]. Wnt ligands bind to
membrane complexes consisting of a seven transmembrane
domain receptor of the frizzled family [3–5] and a ‘single-pass’
co-receptor, Lipoprotein Receptor-Related Protein 6 (Lrp6) and
possibly Lrp5 as well [6–8]. In the absence of stimulation, the Wnt
pathway is under the negative control of a pair of protein-serine
kinases, Glycogen Synthase Kinase 3a and 3b (Gsk3a, Gsk3b),
which phosphorylate b-catenin, a Wnt transducer, resulting in its
ubiquitination and subsequent proteasomal degradation [9,10].
Upon Wnt stimulation, the Gsk3-mediated phosphorylation of b-
catenin is attenuated through disruption of the b-catenin
destruction complex [11]. Subsequently, b-catenin accumulates
and translocates to the nucleus, where it activates Wnt target genes
by associating with the DNA-binding HMG box transcription
factors lymphoid enhancer factor 1 (Lef1), T-cell factor 7 (Tcf7),
Tcf7L1, and/or Tcf7L2 [12–15]. Tcf7, Tcf7L1 and Tcf7L2 are
commonly known as Tcf1, Tcf3, and Tcf4, respectively, and these
common names are used in this paper.
Osteoporosis, the most prevalent degenerative disease in
western societies, is characterized by decreased bone mass and
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uous turnover, where overall bone gain or loss is determined by
the difference between bone resorption and formation. After birth,
bone mass increases until it reaches ‘‘peak bone mass’’, which is
then maintained at a constant level during young adulthood,
followed by an age-related bone loss [16]. Bone mass accrual is
subject to sexual dimorphism, with males having higher trabecular
bone volume density and lower bone turnover than females [16–
19]. The age-related bone loss is associated with reduction in
turnover rate especially in females [20,21].
In humans and mice alike, bone mass is strongly dependent on
the Wnt signaling pathway [22,23]. Mutations and polymorphism
in Wnt10b, Dkk1, Dkk2, Sfrp1, Sost, Lrp6, and Gsk3b affect osteoblast
function and therefore bone formation and bone mass [24–30].
The Wnt pathway has also been implicated in mediating positive
and negative control of bone formation and bone mass by
environmental factors such as pharmacological glucocorticoids
[31–34] and mechanical stimulation [35]. Interestingly, Wnt
signaling in osteoblasts also controls osteoclast activity, as
demonstrated by increased resorption and a low bone mass
(LBM) phenotype in mice whose osteoblasts lack b-catenin or Tcf1
[23]. The role of Lef1 in postnatal bone metabolism has not been
studied, in part because Lef1 deficient mice die within the first
week of life [36].
During early embryogenesis, Tcf1 and Lef1 are redundant.
Mice lacking both genes have multiple defects, including
duplicated neural tubes and malformed limb buds, whereas mice
lacking either gene alone do not exhibit these defects [37,38].
Non-redundant functions of these transcription factors are
suggested by the distinct phenotypes observed in mice lacking
either Tcf1 or Lef1. Whereas Tcf1-null mice display attenuated T
cell differentiation [39], Lef1-null mice exhibit developmental
defects in teeth, hair follicles, mammary glands and the brain
[36,40]. In terms of skeletal metabolism, analysis of Tcf1-null mice
disclosed accelerated bone resorption [23], but similar analysis of
Lef1-null mice is hampered by their perinatal lethality. In this
study, we employed the viable Lef1 haploinsufficient mice, which
do not display the abnormalities observed in the null mice, to
assess the role of Lef1 in postnatal bone metabolism. We
demonstrate a low bone mass phenotype in Lef1
+/2 mice, which
appears to manifest specifically in the context of high bone
turnover rate.
Results
Low bone mass (LBM) phenotype in Lef1 heterozygous
female mice
Micro-computed tomographic (mCT) analysis of 13-week old
Lef1 haploinsufficient female mice revealed a LBM phenotype
compared to littermate controls (Figure 1). The trabecular bone
volume density (BV/TV) measured in the distal femur (Figure 1A)
and the vertebral body (Figure 1C) of Lef1 haploinsufficient mice
was 34% and 17% lower than the wild-type (WT) controls,
respectively. In contrast to females, male mice showed no
difference between Lef1
+/2 and WT animals (Figure 1). The
decrease in BV/TV due to Lef1 haploinsufficiency resembles the
magnitude of trabecular bone loss due to Lrp6 haploinsufficiency
[24].
Detailed analysis of the trabecular bone parameters in the 13-
week old female mice revealed interesting site-specific responses to
Lef1 haploinsufficiency. While the decreased BV/TV at the
vertebral bodies was attributable to thinning of trabeculae, the
LBM at the distal femoral metaphysis was due to decreased
trabecular number (Tb.N) and was also associated with decreased
connectivity density (Conn.D, Figure 1). Skeletal site-specific
control of bone mass, both related and unrelated to the Wnt
signaling pathway, has been previously observed [25,41–44],
although the underlying mechanisms remain to be elucidated. A
similar trabecular bone phenotype was observed in 17-week old
Lef1
+/2 females, and again males were unaffected. At 13 weeks
of age, the Lef1
+/2 females, but not males, also exhibited reduced
cortical bone thickness (0.162 mm vs. 0.188 mm in wild-type
females, p=0.021), but the femoral length and mid-diaphyseal
diameter were unaffected by the Lef1 gene dosage in either
gender (data not shown). Additionally, we did not detect any
skeletal abnormalities in Lef1 knockout newborns, as indicated by
whole mount staining and histological analysis (Figure S1). The
total body weight was similar in Lef1 heterozygous and gender/
age-matched WT controls (data not shown). Thus, Lef1
haploinsufficiency leads to a LBM phenotype specifically in
females, demonstrating for the first time a role for Lef1 in bone
metabolism.
Decreased bone formation in Lef1
+/2 female mice
Wnt signaling has been implicated in both promoting osteoblast
[45] and attenuating osteoclast function [23]. Accordingly, Lef1
haploinsufficiency could lead to a LBM phenotype by either
inhibiting bone formation or stimulating bone resorption. We
therefore assessed trabecular bone formation and resorption in
distal femoral metaphyses of 17-week old Lef1
+/2 mice and
littermate controls using vital calcein labeling and TRAP staining,
respectively. As shown in Figure 2C, Lef1
+/2 female mice
exhibited a 25% lower bone formation rate (BFR) as compared
to WT controls (Figure 2C), attributable mainly to decreased
mineral apposition rate (MAR; Figure 2A), which represents the
activity of the average osteoblast. Thus, the female Lef1
+/2 LBM
phenotype is attributable to reduced osteoblast function. In
contrast, there was no indication for increased bone resorption
in Lef1
+/2 females because they had less, not more TRAP-positive
cells compared to controls (Figure 2D). Importantly, the skeletal
remodeling analysis in male mice revealed no difference between
Lef1
+/2 and Lef1
+/+ animals (Figure 2). On a side note, our
findings demonstrate lower bone turnover in WT male compared
to WT female mice (242.1% MAR; 251.4% BFR and 245.6%
osteoclast number, p,0.05 for each parameter), which is
consistent with previous reports [46,47]. The higher bone turnover
in females compared to males may predispose the formers to Lef1
haploinsufficiency-induced LBM (see below).
We next assessed the effects of Lef1 heterozygocity on Lef1
expression and on osteoblast differentiation in vitro. First, we
confirmed that Lef1 expression was significantly reduced in bones
and in newborn mouse calvarial osteoblast (NeMCO) cultures
derived from Lef1 heterozygous compared to control mice
(Figure 3A–3C). In mesenchymal stem cell (MSC) cultures derived
from bone marrow of female mice, Lef1 haploinsufficiency
increased the number of CFU-F, whereas the number of CFU-
Ob was unchanged (Figure 3D). Interestingly, Lef1 haploinsuffi-
ciency in male mice, which did not reduce bone mass in vivo
(Figure 1), was associated with an increase in bone marrow-
derived CFU-Ob (Figure 3D). In vitro osteoblast differentiation as
defined by mineralization in NeMCO cultures was accelerated by
Lef1 haploinsufficiency (Figure 3E).
High bone mass (HBM) in Gsk3b haploinsufficient female
mice
Alterations in components of the Wnt pathway other than Lef1
may also have stronger skeletal effects in females as compared to
males. To address this notion, we compared the role of Gsk3b,a
Lef1 Regulates Bone Mass
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mass. Because the Gsk3ß-null mice die in utero [48], we analyzed the
trabecular bone in the distal femoral metaphysis of mice
haploinsufficient for Gsk3ß. Indeed, female, but not male
Gsk3b
+/2 mice exhibited a high bone mass (HBM) phenotype
compared to WT littermates (Figure 4A). The elevated BV/TV
was attributable to increased trabecular number, and was
associated with increased connectivity density (Figure 4), a mirror
image of the respective Lef1
+/2 LBM phenotype. Jointly, the
gender-preferential effects of both Lef1 and Gsk3b haploinsuffi-
ciency suggest that the skeleton is more sensitive to variations in
Wnt signaling in females compared to males.
Figure 1. Low trabecular bone mass in Lef1
+/2 female mice. (A,C) mCT analysis of the distal femoral (A) and the vertebral (C) trabecular bone of
Lef1
+/+ (black) and Lef1
+/2 (white) female (left) and male (right) 13-week old mice. BV/TV – trabecular bone volume density, Tb.N – trabecular number,
Tb.Th – trabecular thickness, Conn.D – connectivity density (Mean6SEM of 4–10 specimens as indicated within the bars at the top, *=p,0.05). (B,D)
mCT images of distal femoral (B) and vertebral (D) trabecular bone of female (left) and male (right) 13-week old mice with median BV/TV. Scale
bar=0.5 mm.
doi:10.1371/journal.pone.0005438.g001
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haploinsufficiency
The female-preferential skeletal phenotype of the Lef1
+/2 mice
could be explained by a compensatory gene(s) on the Y
chromosome, hypersensitization by estrogens, or protection by
androgens. In support of the latter possibility, androgens can
augment Wnt signaling [49,50], and even stimulate Lef1
expression in osteoblasts (Figure S2) similar to what has been
observed in adipocytes [51]. To test the hypothesis that
androgen signaling protects against Lef1 haploinsufficiency-
induced LBM in vivo,w ee m p l o y e dtfm male mice, in which
androgen signaling is absent due to a naturally occurring
mutation in the androgen receptor (AR) [52]. To generate
Lef1
+/2;AR
tfm mice, Lef1
+/2 males were bred with female tfm
carriers. Because the AR
tfm allele is embedded in a tabby genomic
sequence [53], we first analyzed the distal femora in offspring
with wild type AR, but which are no longer on a pure C57BL/6
background. Similar to the original results (Figure 1), female
Lef1
+/2 mice that partially carry the tabby genome exhibited a
LBM phenotype (Figure 5Aa, and compare Figure 5Ba to 5Bb),
while male mice on the same genetic background were protected
( F i g u r e5 A c ,a n dc o m p a r eF i g u r e5 B et o5 B f ) .R e m a r k a b l y ,
however, male tfm mice were vulnerable to Lef1 haploinsuffi-
ciency, similar to females (Figure 5). Specifically, Lef1
+/2;AR
tfm
mice had a 22% lower BV/TV as compared to their Lef1
+/+;
AR
tfm counterparts (Figure 5Ad, and compare Figure 5Bg to
5Bh). Similar results were observed in the vertebral bodies
(Figure 5C and 5D). Because estrogen levels in tfm males do not
approach those of females [54], and because these mice still
carry an intact Y chromosome, these results demonstrate that
androgen signaling protects against Lef1 haploinsufficiency-
induced LBM.
Aged females are resistant to Lef1 haploinsufficiency-
induced LBM
It has been previously suggested that androgen signaling can
augment Wnt signaling in bone cells [49,50]. This could explain
how males are protected against Lef1 haploinsufficiency-induced
LBM. Alternatively, androgens could also indirectly protect males
by restraining bone turnover [54,55]. If low bone turnover
protects male mice from Lef1 haploinsufficiency, then Lef1
+/2
females may no longer display a low bone mass phenotype
compared to WT females at ages older than 17 weeks, when bone
turnover decreases [20,21]. Indeed, mCT analysis of 34-week old
female mice revealed no difference between Lef1
+/2 and WT
females (Figure 6). At this age, the male skeleton was again
unaffected by Lef1 haploinsufficiency (Figure 6). In summary, Lef1
haploinsufficiency induces LBM in a gender- and age-specific
manner.
Figure 2. Low bone formation in Lef1
+/2 female mice. Histomor-
phometric analysis of the distal femoral metaphysis from Lef1
+/+ (black)
and Lef1
+/2 (white) female (left) and male (right) 17-week old mice. (A)
mineral apposition rate (MAR), a surrogate for osteoblast activity;
images show representative histological sections from Lef1
+/+ (left) and
Lef1
+/2 (right) females; (B) mineralizing perimeter (Min.Peri), a surrogate
for osteoblast number; (C) bone formation rate (BFR); (D) trabecular
bone osteoclast number (N.Oc/BS). Data represent mean6SEM of 4–9
specimens as indicated within the bars in A; *=p,0.05.
doi:10.1371/journal.pone.0005438.g002
Figure 3. Reduced Lef1 expression is not associated with
impaired osteoblast differentiation in vitro. (A,B) Lef1 mRNA in
tibia of Lef1
+/2 and control male and female mice (A) and in NeMCO
cultures (B) was assessed by RT-qPCR and corrected for the expression
of GAPDH and rpL10A, respectively. Bars represent relative expression
levels (Mean6SEM, n=3). (C) Western blot analysis of Lef1 expression in
NeMCO cultures. Equal loading was demonstrated by Coomassie blue
staining (bottom panel shows a ,60 KDa Coomassie blue-stained
band). (D) Bone marrow mesenchymal cells from WT and Lef1
+/2 mice
of each gender were cultured for 28 days, fixed and stained with
Alizarin red. Colonies were manually counted in each of 6–11
independent cultures for each condition. Alizarin red-positive colonies
were counted as osteoblastic colony-forming units (CFU-Ob), and the
rest were considered fibroblastic CFU (CFU-F). (E) Day-20 NeMCO
cultures from WT and Lef1
+/2 mice were fixed and stained with Alizarin
red. Data represent mean mineralized area relative to WT6SEM in at
least 3 cultures per condition. *=p,0.05 vs. WT.
doi:10.1371/journal.pone.0005438.g003
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The present work demonstrates low bone mass in mice, in
which one Lef1 gene copy is disrupted. Interestingly, bone mass
was reduced in 13- and 17-week old females, but not in males of
any age or in 34-week old females. This gender-specificity reflected
neither protection by a Y chromosome-associated gene nor
sensitization by estrogens, since Lef1
+/2 male mice harboring a
testicular feminization mutation (tfm) also displayed a LBM
phenotype despite their having an intact Y chromosome and not
having feminine estrogen levels [54]. Gsk3b
+/2 mice displayed a
mirror image of the Lef1
+/2 phenotype, namely increased bone
mass in female mice only. In line with our findings, disruption of
Sfrp1, a Wnt antagonist, resulted in a female-preferential bone
phenotype [29]. Thus, genetic alterations in components of the
Wnt pathway appear to affect female more than male mice. That
Lrp5 deficiency reduces bone mass equally in males and females
[56] is not inconsistent with our conclusion in light of the recent
work of Yadav et al. [57], who disputed the paradigm that places
Lrp5 upstream of Gsk3b and Lef1 in osteoblasts. Plausibly, a
genetic lesion at the level of Lef1 itself compromises canonical Wnt
signaling and is therefore more consequential in females than in
males.
All mice that were sensitive to Lef1 haploinsufficiency in our
study, namely young females and tfm males, are also characterized
by a relatively high rate of bone turnover (Figure 2 and ref. [54]).
In contrast, mice resistant to Lef1 haploinsufficiency—AR
WT males
and aged females (Figure 1, Figure 5, Figure 6)—have a lower rate
of bone turnover (Figure 2 and [20,21]). Thus, a unifying
explanation for our observations is that bone turnover rate
determines the skeletal response to genetic alterations in canonical
Wnt signaling. Our favored interpretation of the gender-specific
sensitivity to Lef1 haploinsufficiency is that androgens protect the
skeleton from the potential deleterious effect of reduced Lef1 by
restraining bone turnover [54,55].
We cannot rule out an alternative explanation whereby AR
activity compensates for Lef1 haploinsufficiency via molecular
interaction with the canonical Wnt pathway. In fact, it has been
shown that DHT stimulates Lef/Tcf-mediated transcription in
osteoblasts [49,50]. This could occur via physical interaction of
liganded AR with b-catenin [51] or with membrane residents such
as Src [58], which could then impinge on the Wnt pathway
through activation of the PI3 kinase/Akt/Gsk3b axis [50,59,60].
Alternatively, androgens could regulate the expression of either
Lef1 itself (Figure S2 and [51]) or Wnt agonists and/or antagonists
[61]. However, the normal bone phenotype observed in 34-week
old Lef1
+/2 female mice favors the hypothesis that androgen
signaling, much like aging in females, overrides the skeletal
sensitivity to Lef1 haploinsufficiency by restraining bone turnover.
Obviously, the two explanations for AR-mediated protection
against Lef1 haploinsufficiency – molecular interaction with the
Wnt pathway and attenuation of bone turnover – are not mutually
exclusive.
It remains to be examined to what extent the effect of Lef1 on
bone formation is cell autonomous. In favor of cell autonomy is the
reduced Lef1 expression in Lef1
+/2 osteoblasts and the observed
gender-dependent changes in the numbers of CFU-F and CFU-
Ob in bone marrow-derived MSCs cultures (Figure 3D). Possibly,
Lef1 haploinsufficiency promotes premature osteoblast differenti-
ation ([62,63] and Figure 3E). However, much like the effect of
duodenal Lrp5 [57], the role of Lef1 in regulating bone formation
may reside in cells other than osteoblasts. Cell type-specific
knockout studies will be necessary to clarify this issue.
An intriguing, albeit speculative, extrapolation from our
findings is that females reach lower peak bone mass than males
because, in the absence of androgens, higher rate of bone turnover
renders the young female skeleton more vulnerable to sub-optimal
activity of canonical Wnt signaling and possibly other pathways.
Other investigators reported on age- and gender-dependent bone
phenotypes in mice with genetic alterations in different pathways.
For example, osteoblast-specific disruption of BMP type-IA
receptor leads to LBM in young mice but HBM in old mice
[64]. Very similar age-dependent effects were reported for Runx2
haploinsufficiency in mice [20]. In addition, the strong anabolic
effect of estrogen in young Runx2
+/2 mice was almost completely
abolished in aged mice [20]. With regard to gender specificity, and
Figure 4. High trabecular bone mass in Gsk3b
+/2 female mice. (A) mCT analysis of the distal femoral trabecular bone of 16 week old Gsk3b
+/+
(black) and Gsk3b
+/2 (white) female (left) and male (right) mice. Data represent mean6SEM of 6–14 specimens as indicated within the bars at the top,
*=p,0.05. (B) mCT images from female (left) and male (right) mice with median BV/TV. Scale bar=0.5 mm.
doi:10.1371/journal.pone.0005438.g004
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PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5438Figure 5. Androgen signaling protects against Lef1 haploinsufficiency-induced low bone mass. mCT analysis of the trabecular bone
compartment in distal femora (A,B) and vertebral bodies (C,D) of 13-week old female (left) and male (right) Lef1
+/+ (black) and Lef1
+/2 (white) mice.
AR
tfm males have no functional AR, while AR
tfm females are carriers for the defective AR allele. Data represent mean6SEM of 9–20 specimens as
indicated within the bars at the top, *=p,0.05. (B) and (D) show respective mCT images of female (left) and male (right) mice with median BV/TV.
Mice in a, b, e and f carry the wild-type AR (AR
WT); mice in c, d, g and h carry the AR
tfm allele; mice in a, c, e and g are Lef1
+/+; mice in b, d, f and h are
Lef1
+/2. Scale bar=0.5 mm.
doi:10.1371/journal.pone.0005438.g005
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manipulation of Lef1, GSK3ß and Sfrp1, ablation of Cathepsin K
results in a 3-fold stronger effect in female compared to male mice
[47]. Age- and gender-related variations in bone turnover may
explain the differential skeletal responses to some of these and
other genetic aberrations. Furthermore, hormonal and age-related
variation in bone turnover may contribute to gender- and age-
related susceptibility to osteoporosis and response to therapies.
Materials and Methods
Animals
Lef1
+/2 and Gsk3b
+/2 mice and their controls, all on a C57BL/
6 background, were generated by breeding Lef1
+/2 [36] or Gsk3b
+/2
[26] mice with C57BL/6 mice from either Harlan Laboratories
(Indianapolis, Indiana, USA) or the Ontario Cancer Institute
(Toronto, Canada), respectively. Mice carrying the testicular
feminization mutation (Tfm) (Jackson Laboratories, Bar Harbor,
Maine, USA) on a C57BL/6J-A-Ta,6J. background were bred
with the Lef1
+/2 mice and F1 litters were examined. To measure the
percentage of bone surface undergoing mineralization and the
mineralization rate, mice were injected intraperitoneally with 15 mg/
kg of the fluorochrome calcein (Sigma-Aldrich, St. Louis, MO, USA)
four days and againoneday prior tosacrifice. Onefemur and the fifth
lumbar vertebra (L5) from each mouse were dissected and fixed in
10% phosphate-buffered formalin (pH=7.2) for 24 hours, and then
stored in 70% ethanol. All experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) of the
University of Southern California and of the University of Toronto.
Micro-computed tomography
Femora (one per mouse) and fifth lumbar vertebrae (L5) were
examined as reported previously [65,66] using either Scanco mCT
40 (Scanco Medical AG, Bru ¨ttisellen, Switzerland), or Siemens
MicroCAT II (Siemens Medical Solutions, Knoxville, TN, USA).
Briefly, scans were performed at a 20-mm resolution in all three
spatial dimensions. The mineralized tissues were differentially
segmented by a global thresholding procedure [67]. Trabecular
parameters in the secondary spongiosa of the distal femoral
metaphysis included trabecular bone volume density (BV/TV),
trabecular thickness (Tb.Th), trabecular number (Tb.N) and
connectivity density (Conn.D). Cortical thickness, diaphyseal
diameter, and medullary cavity diameter were determined in the
mid-diaphyseal region. In L5 bodies, the entire trabecular bone
compartment was analyzed. All morphometric parameters were
determined by using a direct 3D approach [68]. Differences
between groups were analyzed by student’s t-test (two-tailed) and
were considered significant when p,0.05.
Histomorphometry
After mCT image acquisition, femora were embedded unde-
calcified in polymethylmethacrylate (Technovit 9100, Heraeus
Kulzer, Germany). Undeplasticized longitudinal 5-mm sections
from the center of each bone were left unstained for dynamic
histomorphometric measurements. To identify osteoclasts, con-
secutive sections were deplasticized and stained with tartrate-
resistant acid phosphatase (TRAP; Sigma-Aldrich, St. Louis, MO,
USA) and counterstained with Mayer’s hematoxylin [69]. The
morphometric analysis was performed using the Image-Pro
Figure 6. Thirty four-week old female mice are insensitive to Lef1 haploinsufficiency. (A,B) mCT analysis of the distal femoral (A) and the
vertebral (B) trabecular bone of Lef1
+/+ (black) and Lef1
+/2 (white) female (left) and male (right) 34-week old mice (Data represent mean6SEM of 7–11
specimens as indicated within the bars at the top).
doi:10.1371/journal.pone.0005438.g006
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The following parameters were determined: mineral apposition
rate (MAR), mineralizing perimeter (Min.Peri), bone formation
rate (BFR) and osteoclast number (N.Oc/BS). The terminology
and units used for these measurements were according to the
convention of standardized nomenclature [70]. Statistical analysis
was performed as above.
Tissue culture
NeMCO cultures were prepared from one day-old pups as
described previously [71]. Cells were cultured in 6-well plates for
Western blot analysis and in 12-well plates for RT-qPCR and
mineralization assays. For the latter, osteogenic medium contain-
ing ascorbic acid (50 mg/mL) and b-glycerophosphate (10 mM)
was initiated at confluence and alizarin red staining was performed
at day 20. For MSC cultures, the cellular content of the bone
marrow cavity from two femurs and two tibiae from each mouse
was flushed using aMEM and passed through needles with
decreasing diameters (down to 25G) to obtain a single cell
suspension. Cells were then plated at 3610
6 per well in 6-well
plates and incubated for 3 days in aMEM (Invitrogen)
supplemented with 15% FBS (Gemini Bio-Products, West
Sacramento, CA). Starting at day 3, the MSC were cultured in
osteogenic medium and stained with Alizarin red after 28 days.
Lef1 expression
Total RNA was extracted from freshly isolated tibiae of 10
week-old mice. Upon harvesting, one tibia per animal was
stabilized in RNALater (Ambion, Austin, TX), homogenized in
Trizol (Invitrogen), purified using 1-Bromo-3-Chloropropane and
isopropanol, then rinsed in 70% ethanol. RNA from cells was
extracted using Aurum Total RNA Mini Kit (Biorad, Hercules,
CA). cDNA was produced using Superscript III First Strand
cDNA synthesis kit (Invitrogen) and Real-Time PCR was
performed using iQ SYBR green supermix (Biorad) and an
Opticon 2 real time PCR machine (Biorad). Lef1 mRNA levels in
tibiae and NeMCO cultures were corrected for GAPDH and
ribosomal protein L10A (rpL10A) mRNA, respectively. Primers
used for PCR are listed in Table 1. Western blot analysis of Lef1 in
NeMCO cultures was performed essentially as previously
described [71] using anti-Lef1 antibody from Cell Signaling
(Danvers, MA) and secondary antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA).
Supporting Information
Figure S1 Lef1
2/2 mice have normal bone development.
Histological evaluation of wild type (a–e) versus Lef1
2/2 (f–j)
newborn mice. (a,b,f,g) Alizarin red/Alcian blue staining of
craniofacial bones. (c,h) Alizarin red/Alcian blue staining of hind
limb and vertebrae. (d,i) H-E staining of longitudinal femoral
sections. (e,j) Toluidine blue staining of distal femoral growth
plates. Representative images are shown. No abnormality was
detected in the Lef1
2/2 skeletons, except for the previously
reported lack of teeth (f) (van Genderen et al. 1994, Genes Dev 8,
2691-703)
Found at: doi:10.1371/journal.pone.0005438.s001 (3.47 MB TIF)
Figure S2 DHT stimulates Lef1 expression in vitro. MC3T3-E1
osteoblast cultures maintained in phenol-red free aMEM supple-
mented with 10% charcoal-stripped serum were treated with
30 nM DHT or 100 nM estradiol for 48 hours. Expression of the
four members of the Lef/Tcf gene family was assessed by RT-
qPCR and corrected for the expression of rpL10A. Bars represent
expression levels in the presence of hormone relative to the ethanol
vehicle, defined for each gene as 1.
Found at: doi:10.1371/journal.pone.0005438.s002 (0.88 MB TIF)
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